We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Atea Pharmaceuticals Inc
20 own
23 watching
Current Price
$4.51
$-0.23
(-4.85%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
375.63M
52-Week High
9.79
52-Week Low
4.175
Average Volume
0.88M
Dividend Yield
--
P/E Ratio
26.9871
Market Capitalization375.63M52-Week High9.7952-Week Low4.175Average Volume0.88MDividend Yield--P/E Ratio26.9871What does the Atea Pharmaceuticals Inc do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More
How much money does Atea Pharmaceuticals Inc make?
News & Events about Atea Pharmaceuticals Inc.
Globe Newswire
26days ago
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination ...
Zolmax
11 months ago
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its price objective lowered by JPMorgan Chase & Co. from $10.00 to $8.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock. A number of other research analysts have also ...
Fool.com Headlines
11 months ago
The stock market was mixed on Monday as investors tried to reconcile everything happening around the world.February came to a close on a mixed note for Wall Street, with investors struggling to deal with all the uncertainty present in the stock market right now. The Dow Jones Industrial Average (...
Benzinga
11 months ago
Companies Reporting Before The Bell
Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Atea Pharmaceuticals Inc share price today?
Can Indians buy Atea Pharmaceuticals Inc shares?
How can I buy Atea Pharmaceuticals Inc shares from India?
Can Fractional shares of Atea Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Atea Pharmaceuticals Inc stocks?
What is today’s traded volume of Atea Pharmaceuticals Inc?
What is today’s market capitalisation of Atea Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Atea Pharmaceuticals Inc?
What percentage is Atea Pharmaceuticals Inc down from its 52-Week High?
What percentage is Atea Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$4.51
$-0.23
(-4.85%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.